|
1
|
Ismail-Khan R, Robinson LA, Williams CC
Jr, Garrett CR, Bepler G and Simon GR: Malignant pleural
mesothelioma: A comprehensive review. Cancer Control. 13:255–263.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsiouris A and Walesby RK: Malignant
pleural mesothelioma: Current concepts in treatment. Nat Clin Pract
Oncol. 4:344–352. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lin RT, Takahashi K, Karjalainen A,
Hoshuyama T, Wilson D, Kameda T, Chan CC, Wen CP, Furuya S, Higashi
T, et al: Ecological association between asbestos-related diseases
and historical asbestos consumption: An international analysis.
Lancet. 369:844–849. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takahashi K and Landrigan PJ: Collequim
Ramazzini: The global health dimensions of asbestos and
asbestos-related diseases. Ann Glob Health. 82:209–213. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tomasson K, Gudmundsson G, Briem H and
Rafnsson V: Malignant mesothelioma incidence by nation-wide cancer
registry: A population-based study. J Occup Med Toxicol. 11:372016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Scherpereel A, Astoul P, Baas P, Berghmans
T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin
C, Hillerdal G, et al: Guidelines of the European Respiratory
Society and the European Society of Thoracic Surgeons for the
management of malignant pleural mesothelioma. Eur Respir J.
35:479–495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stahel RA, Weder W, Lievens Y and Felip E:
ESMO Guidelines Working Group: Malignant pleural mesothelioma: ESMO
clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 21 Suppl 5:v126–v128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van der Bij S, Schaake E, Koffijberg H,
Burgers JA, de Mol BA and Moons KG: Markers for the non-invasive
diagnosis of mesothelioma: A systematic review. Br J Cancer.
104:1325–1333. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hollevoet K, Reitsma JB, Creaney J,
Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI,
Nackaerts K, Portal Rodríguez JA, et al: Serum mesothelin for
diagnosing malignant pleural mesothelioma: An individual patient
data meta-analysis. J Clin Oncol. 30:1541–1549. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tanaka F, Yoneda K and Hasegawa S:
Circulating tumor cell (CTC) in lung cancer: Current status and
future perspectives. Lung Cancer (Auckl). 1:77–84. 2010.PubMed/NCBI
|
|
11
|
Tanaka F and Yoneda K: Adjuvant therapy
following surgery in non-small cell lung cancer (NSCLC). Surg
Today. 46:25–37. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Allard WJ, Matera J, Miller MC, Repollet
M, Connely MC, Rao C, Tibbe AGJ, Uhr JW and Terstappen LW: Tumor
cells circulate in the peripheral blood of all major carcinomas but
not in healthy subjects or patients with nonmalignant diseases.
Clin Cancer Res. 10:6897–6904. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoneda K, Tanaka F, Kondo N, Hashimoto M,
Takuwa T, Matsumoto S, Okumura Y, Tsubota N, Sato A, Tsujimura T,
et al: Circulating tumor cells (CTCs) in malignant pleural
mesothelioma (MPM). Ann Surg Oncol. 21 Suppl 4:S472–S480. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ohnaga T, Shimada Y, Moriyama M, Kishi H,
Obata T, Takata K, Okumura T, Nagata T, Muraguchi A and Tsukada K:
Polymeric microfluidic devices exhibiting sufficient capture of
cancer cell line for isolation of circulating tumor cells. Biomed
Microdevices. 15:611–616. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chikaishi Y, Yoneda K, Ohnaga T and Tanaka
F: EpCAM-independent capture of circulating tumor cells with a
‘universal CTC-chip’. Oncol Rep. 37:77–82. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Usami N, Fukui T, Kondo M, Taniguchi T,
Yokoyama T, Mori S, Yokoi K, Horio Y, Shimokata K, Sekido Y and
Hida T: Establishment and characterization of four malignant
pleural mesothelioma cell lines from Japanese patients. Cancer Sci.
97:387–394. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kimura N and Kimura I: Podoplanin as a
marker for mesothelioma. Pathol Int. 55:83–86. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Abe S, Morita Y, Kaneko MK, Hanibuchi M,
Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, et al: A
novel targeting therapy of malignant mesothelioma using
anti-podoplanin antibody. J Immunol. 190:6239–6249. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ordóñez NG: D2-40 and podoplanin are
highly specific and sensitive immunohistochemical markers of
epithelioid malignant mesothelioma. Hum Pathol. 36:372–380. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Toss A, Mu Z, Fernandez S and
Cristofanilli M: CTC enumeration and characterization: Moving
toward personalized medicine. Ann Transl Med. 2:1082014.PubMed/NCBI
|
|
21
|
Nagrath S, Sequist LV, Maheswaran S, Bell
DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky
A, et al: Isolation of rare circulating tumour cells in cancer
patients by microchip technology. Nature. 450:1235–1239. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Husain AN, Colby TV, Ordóñez NG, Krausz T,
Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs
AR, et al: Guidelines for pathologic diagnosis of malignant
mesothelioma: A consensus statement from the international
mesothelioma interest group. Arch Pathol Lab Med. 133:1317–1331.
2009.PubMed/NCBI
|
|
23
|
Scales SJ, Gupta N, Pacheco G, Firestein
R, French DM, Koeppen H, Rangell L, Barry-Hamilton V, Luis E, Chuh
J, et al: An antimesothelin-monomethyl auristatin e conjugate with
potent antitumor activity in ovarian, pancreatic, and mesothelioma
models. Mol Cancer Ther. 13:2630–2640. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sato A, Torii I, Okamura Y, Yamamoto T,
Nishigami T, Kataoka TR, Song M, Hasegawa S, Nakano T, Kamei T and
Tsujimura T: Immunocytochemistry of CD146 is useful to discriminate
between malignant pleural mesothelioma and reactive mesothelium.
Mod Pathol. 23:1458–1466. 2010. View Article : Google Scholar : PubMed/NCBI
|
